Garg H, Hada RS, Gupta JC, Talwar GP, Dubey S. Combination immunotherapy with Survivin and luteinizing hormone-releasing hormone fusion protein in murine breast cancer model. World J Clin Oncol 2018; 9(8): 188-199 [PMID: 30622927 DOI: 10.5306/wjco.v9.i8.188]
Corresponding Author of This Article
Shweta Dubey, PhD, Associate Professor, Amity Institute of Virology and Immunology, Amity University Uttar Pradesh, J-3 Block, Room No: LG21, Sector 125, Noida 201303, Uttar Pradesh, India. sdubey@amity.edu
Research Domain of This Article
Oncology
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Dec 20, 2018; 9(8): 188-199 Published online Dec 20, 2018. doi: 10.5306/wjco.v9.i8.188
Combination immunotherapy with Survivin and luteinizing hormone-releasing hormone fusion protein in murine breast cancer model
Himani Garg, Rohit Singh Hada, Jagdish C Gupta, G P Talwar, Shweta Dubey
Himani Garg, Rohit Singh Hada, Jagdish C Gupta, G P Talwar, Talwar Research Foundation, Neb Sarai, New Delhi 110068, India
Himani Garg, Shweta Dubey, Amity Institute of Virology and Immunology, Amity University Uttar Pradesh, Noida 201303, Uttar Pradesh, India
Author contributions: Gupta JC and Dubey S shared corresponding authorship; Garg H and Hada RS conducted and analysed the experiments; Gupta JC and Dubey S designed the study and wrote the manuscript; Talwar GP edited the manuscript.
Institutional animal care and use committee statement: All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of the Amity Institute of Pharmacy, Amity University, Noida, UP, India (IACUC protocol number: AIP/CPSCEA/PRO/01/2015).
Conflict-of-interest statement: To the best of our knowledge, no conflict of interest exists.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author to: Shweta Dubey, PhD, Associate Professor, Amity Institute of Virology and Immunology, Amity University Uttar Pradesh, J-3 Block, Room No: LG21, Sector 125, Noida 201303, Uttar Pradesh, India. sdubey@amity.edu
Telephone: +91-120-4586865 Fax: +91-120-4392320
Received: June 16, 2018 Peer-review started: June 17, 2018 First decision: July 19, 2018 Revised: August 24, 2018 Accepted: November 4, 2018 Article in press: November 4, 2018 Published online: December 20, 2018 Processing time: 188 Days and 17.8 Hours
Core Tip
Core tip: Targeting Survivin for treatment of cancer is an emerging trend in cancer immunotherapy. In this study we optimized the dose of recombinant full-length Survivin for tumor growth inhibition. Since luteinizing hormone-releasing hormone (LHRH) is also known to support breast cancer in case of premenopausal women, we combined recombinant LHRH fusion protein with Survivin and Mycobacterium indicus pranii and obtained a positive anti-tumor response. We report our results of using recombinant Survivin protein and LHRH fusion protein as potential vaccine antigens for immunotherapy of murine model of breast cancer which was developed by injecting 4T-1 mammary cell line in syngeneic Balb/c mice. Immunized mice challenged with syngeneic 4T-1 cells exhibited suppression of tumor growth and metastasis in lungs in comparison to control mice.
